Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Summary

This is a prospective, single institution phase II study, whose primary objective is to estimate the median and three year survival rate of non-small lung cancer patients with Stage IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small cell lung cancer (NSCLC).

Timeline

Start

2014-10

Primary completion

2017-09-27

Completion

2017-09-27

Outcome

Outcome not reported

Stopped: “PI decided to terminate study”

Drugs

Indications